公开(公告)号：US09631240B2

公开(公告)日：2017-04-25

申请号：US14199738

申请日：2014-03-06

Applicant: Genentech, Inc.

Inventor： Zhengyan Kan ,  Denise M. Kenski ,  Brock Peters ,  Somasekar Seshagiri

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/156

Abstract: Nucleotide and amino acid variations associated with tumors are provided. Methods for detecting variations and for diagnosing and treating tumors are provided.

公开(公告)号：US20140011821A1

公开(公告)日：2014-01-09

申请号：US13972527

申请日：2013-08-21

Applicant: GENENTECH, INC.

Inventor： Somasekar Seshagiri

IPC: C12Q1/68

CPC classification number: A61K31/517 ,  A61K31/19 ,  A61K31/498 ,  A61K31/704 ,  A61K31/7072 ,  A61K45/06 ,  C12Q1/485 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/16 ,  G01N33/57492 ,  G01N2333/71 ,  G01N2500/00

Abstract: The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.

Abstract translation: 本发明涉及表皮生长因子受体（EGFR）中的突变和检测这种突变的方法以及用于鉴定对抗癌治疗如化疗和/或激酶抑制剂治疗敏感的肿瘤的预后方法。 所述方法包括确定肿瘤样品中突变的EGFR基因或突变的EGFR蛋白的存在，由此突变的EGFR基因或蛋白质的存在表明肿瘤易于治疗。